is dulaglutide a glp-1 Battle of delivery technologies Articles on Trulicity and Diabetes
Description
P.ZaffutoK
Based on positive clinical trial results, Novo Nordisk recently received approval from the FDA to add a new indication to Victoza: lowering cardiovascular risks in type 2 diabetes patients with established cardiovascular disease [178]
Resting heart rate: risk indicator and emerging risk factor in cardiovascular disease
Localized cutaneous amyloidosis at the injection site has occurred
The primary outcome of weight change between the inulin and cellulose groups was calculated using an ANCOVA with baseline weight as a covariate
